EPISODE · Jul 10, 2018 · 34 MIN

James Williams, MS, DO, FACEP - NOAC Update

from ACEP Frontline - Emergency Medicine

The popularity of NOACs has grown. Numerically, though they are safe, it’s likely that the Emergency Physician will see more and more bleeds, especially in a trauma situation. In early May, Portola Pharmaceuticals got FDA approval for the targeted reversal agent, Andexanet, as indicated for the reversal of Eliquis and Xarelto. Dr. Williams breaks down the research on this episode of ACEP’s Frontline. Support for this segment was provided in-part by Portola Pharmaceuticals.